Top

Published in:

01-07-2017 | Short Communication

ATM mutations for surgeons

Authors: Sara A. Mansfield, Robert Pilarski, Doreen M. Agnese

Published in: Familial Cancer | Issue 3/2017

Abstract

The ataxia-telangiectasia mutated (ATM) gene encodes a protein kinase involved in DNA repair. Heterozygotic carriers are at an increased risk of developing breast cancer. As the use of genetic testing increases, identification of at-risk patients will also increase. The aim of this study is to review two cases of heterozygous ATM mutation carriers and review the literature to clarify the cancer risks and suggested management for breast surgeons who will be intimately involved in the care of these patients.

Shiloh Y, Ziv Y (2013) The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol 14:197–210CrossRef

Chaudhary MW, Al-Baradie RS (2014) Ataxia-telangiectasia: future prospects. Appl Clin Genet 7:159–167PubMedPubMedCentral

Swift M, Sholman L, Perry M, Chase C (1976) Malignant neoplasms in the families of patients with ataxia-telangiectasia. Cancer Res 36:209–215PubMed

Marabelli M, Cheng S, Parmigiani G (2016) Penetrance of ATM gene mutations in breast cancer: a meta-analysis of different measures of risk. Genet Epidemiol 40(5):425–431CrossRefPubMed

Hall MJ, Forman AD, Pilarski R, Wiesner G, Giri VN (2014) Gene panel testing for inherited cancer risk. J Natl Compr Canc Netw 12(9):1339–1346CrossRefPubMed

Turnbull C, Rahman N (2008) Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genom Hum Genet 9:321–345CrossRef

NCCN Clinical Practice Guielines in Oncology (NCCN Guidelines) (2016) Genetic/familial high risk assessment: breast and ovarian, Version 2.2017. https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed 7 Dec 2016

Ahmed M, Rahman N (2006) ATM and breast cancer susceptibility. Hum Mutat 27:1122–1128CrossRef

Renwick A, Thompson D, Seal S et al; Breast Cancer Susceptibility Collaboration (UK) (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 38:873–875CrossRefPubMed

10.

Bernstein JL, Teraoka S, Southey MC et al (2006) Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T > G and c.1066-6T > G (IVS10-6T > G) from the Breast Cancer Family Registry. Hum Mutat 27:1122–1128CrossRefPubMed

11.

Tavtigian SV, Oefner PJ, Babikyan D, Hartmann A, Healey S, Le Calvez-Kelm F, Lesueur F, Byrnes GB, Chuang SC, Forey N, Feuchtinger C, Gioia L, Hall J, Hashibe M, Herte B, McKay-Chopin S, Thomas A, Vallée MP, Voegele C, Webb PM, Whiteman DC; Australian Cancer Study; Breast Cancer Family Registries (BCFR); Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab), Sangrajrang S, Hopper JL, Southey MC, Andrulis IL, John EM, Chenevix-Trench G (2009) Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet 85(4):427–446CrossRefPubMedPubMedCentral

12.

Bernstein JL, Teraoka S, Southey MC, Jenkins MA, Andrulis IL, Knight JA, John EM, Lapinski R, Wolitzer AL, Whittemore AS, West D, Seminara D, Olson ER, Spurdle AB, Chenevix-Trench G, Giles GG, Hopper JL, Concannon P (2006) Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T > G and c.1066-6T > G (IVS10-6T > G) from the Breast Cancer Family Registry. Hum Mutat 27(11):1122–1128CrossRefPubMed

13.

Goldgar DE, Healey S, Dowty JG et al (2011) Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res 13:R73CrossRefPubMedPubMedCentral

14.

Gutiérrez-Enríquez S, Fernet M, Dörk T et al (2004) Functional consequences of ATM sequence variants for chromosomal radiosensitivity. Genes Chromosom Cancer 40:109–119CrossRefPubMed

15.

Mao JH, Wu D, DelRosario R, Castellanos A, Balmain A, Perez-Losada J (2008) Atm heterozygosity does not increase tumor susceptibility to ionizing radiation alone or in a p53 heterozygous background. Oncogene 27:6596–6600CrossRefPubMed

16.

Mauer CB, Pirzadeh-Miller SM, Robinson LD, Euhus DM (2013) The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience. Genet Med 16:407–412CrossRefPubMed

17.

Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, Gallinger S, Schwartz AG, Syngal S, Cote ML, Axilbund J, Schulick R, Ali SZ, Eshleman JR, Velculescu VE, Goggins M, Vogelstein B, Papadopoulos N, Hruban RH, Kinzler KW, Klein AP (2012) ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2(1):41–46CrossRefPubMed

18.

Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, Nio Y, Schulick RS, Bassi C, Kluijt I, Levy MJ (2013) International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62(3):339–347CrossRefPubMed

Title: ATM mutations for surgeons
Authors: Sara A. Mansfield
Robert Pilarski
Doreen M. Agnese
Publication date: 01-07-2017
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 3/2017
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-016-9959-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

The hereditary nature of small cell carcinoma of the ovary, hypercalcemic type: two new familial cases

Mutation screening of ACKR3 and COPS8 in kidney cancer cases from the CONFIRM study

Gastric tumours in FAP

Patients with negative multi-gene panel testing: a back to the future paradox?

Biallelic BRCA2 mutations in two black South African children with Fanconi anaemia

Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls

Keynote webinar | Spotlight on antibody–drug conjugates in cancer